Immuneering Corp
NASDAQ:IMRX
Intrinsic Value
Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of IMRX.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Immuneering Corp's business.
What risks and challenges
does Immuneering Corp face in the near future?
Summarize the latest earnings report
of Immuneering Corp.
Provide P/E
for Immuneering Corp and its competitors.
Balance Sheet Decomposition
Immuneering Corp
Current Assets | 89.1m |
Cash & Short-Term Investments | 85.7m |
Other Current Assets | 3.4m |
Non-Current Assets | 13.5m |
PP&E | 5.4m |
Intangibles | 7.1m |
Other Non-Current Assets | 1m |
Current Liabilities | 7.8m |
Accounts Payable | 2.1m |
Accrued Liabilities | 5.5m |
Other Current Liabilities | 259.8k |
Non-Current Liabilities | 4.2m |
Other Non-Current Liabilities | 4.2m |
Earnings Waterfall
Immuneering Corp
Revenue
|
0
USD
|
Operating Expenses
|
-58.4m
USD
|
Operating Income
|
-58.4m
USD
|
Other Expenses
|
4.9m
USD
|
Net Income
|
-53.5m
USD
|
Free Cash Flow Analysis
Immuneering Corp
What is Free Cash Flow?
IMRX Profitability Score
Profitability Due Diligence
Immuneering Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Immuneering Corp's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
IMRX Solvency Score
Solvency Due Diligence
Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Immuneering Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMRX Price Targets Summary
Immuneering Corp
According to Wall Street analysts, the average 1-year price target for IMRX is 15 USD .
Ownership
IMRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IMRX Price
Immuneering Corp
Average Annual Return | -39.91% |
Standard Deviation of Annual Returns | 51.61% |
Max Drawdown | -94% |
Market Capitalization | 84.6m USD |
Shares Outstanding | 29 283 300 |
Percentage of Shares Shorted | 17.12% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. The company is headquartered in Cambridge, Massachusetts and currently employs 64 full-time employees. The company went IPO on 2021-07-30. The firm is focused on improving patient outcomes by advancing a pipeline of oncology and neuroscience product candidates developed using its translational bioinformatics platform. Its development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Its lead product candidate, IMM-1-104, is designed to be a selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. The firm's oncology programs target mutations of the RAS/RAF/MEK/ERK, (MAPK) and the PI3K/AKT/mTOR (mTOR), pathways. Its oncology programs include Dual-MEK: IMM-1-104, MEK-io, Trifecta-MEK, KRAS4B, RAS Induction, Covalent-MEK, and PI3K-alpha. The firm's neuroscience pipeline on Alzheimer's Disease (AD). Its neuroscience programs include IMM-ALL-01 and IMM-ALL-03.